Skip to main content

Long-Acting Injectable Antipsychotics & Mortality

Basic Details
Status
Ongoing
Last Updated
Friday, May 1, 2026
Original Posting Date
Health Outcome(s)
mortality
Purpose
Drug and Outcome Analysis
Meets requirements of FD&C Act Sec 505(o) prior to requiring a PMR
No
Analytic Code Link(s) (3)
Mortality Following Long-Acting Injectable Antipsychotics Use: An Inverse Probability of Treatment Weighting Analysis Mortality Following Long-Acting Injectable Antipsychotics Use: An Updated Inverse Probability of Treatment Weighting Analysis Mortality Following Long-Acting Injectable Antipsychotics Use: A Third Inverse Probability of Treatment Weighting Analysis
Result(s) (6)
Counts and Characteristics of Long-Acting Injectable Antipsychotic (LAIA) Users: A Descriptive Analysis Utilization and Coding Patterns of Long-Acting Injectable Antipsychotics (LAIA): A Descriptive Analysis Mortality Following Long-Acting Injectable Antipsychotics Use: An Updated Inverse Probability of Treatment Weighting Analysis Mortality Following Long-Acting Injectable Antipsychotics Use: A Third Inverse Probability of Treatment Weighting Analysis Counts of and Characterization of Mortality Capture Among Long-Acting Injectable Antipsychotic (LAIA) Users: A Descriptive Analysis Mortality Following Long-Acting Injectable Antipsychotics Use: An Inverse Probability of Treatment Weighting Analysis